A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
نویسندگان
چکیده
Background Over 90% of allergic rhinitis (AR) patients have ocular symptoms during the pollen season, but these are routinely neglected and under-treated. New treatment options should provide relief not only from all nasal symptoms, but all ocular symptoms too, since patients frequently present with symptoms from both nasal and ocular origin. The reflective total of 7 symptom scores (rT7SS) is an endpoint measuring the entire AR symptom complex. It comprises both the reflective total nasal symptom score (rTNSS) and the reflective total ocular symptom score in one global score (max score=42).
منابع مشابه
The journey from unmet need in allergic rhinitis to rationale for, and clinical development of, a new treatment option, MP29-02
• Currently considered first-line allergic rhinitis (AR) therapy provides insufficient symptom relief for many AR patients. • MP29-02 (Dymista®, Meda AB, Solna, Sweden) is a new intranasal AR therapy, consisting of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in a novel and patented formulation and advanced device. • It is indicated for the symptomatic relief of moderate/sever...
متن کاملEscaping the trap of allergic rhinitis
Rhinitis is often the first symptom of allergy but is frequently ignored and classified as a nuisance condition. Ironically it has the greatest socioeconomic burden worldwide caused by its impact on work and on daily life. However, patients appear reticent to seek professional advice, visiting their doctor only when symptoms become 'intolerable' and often when their usual therapy proves ineffec...
متن کاملA new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis.
BACKGROUND AND OBJECTIVE MP29-02 (Dymista), a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP), is significantly better than first-line therapy for the treatment of moderate-to-severe seasonal allergic rhinitis (SAR), and is well tolerated following 52 weeks of continuous use in chronic rhinitis. The aim of this study was to evaluate the long-term e...
متن کاملA new allergic rhinitis therapy (MP29-02*) provides effective and rapid symptom relief for patients who suffer most from the bothersome symptoms of nasal congestion or ocular itch
Background Allergic rhinitis (AR) patients often present with a predominant symptom. Nasal congestion and ocular symptoms have the greatest negative impact on patients’ quality of life [1]. Our aim was to assess the efficacy of MP29-02* (a novel intranasal formulation of azelastine hydrochloride [AZE] and fluticasone propionate [FP] in an advanced delivery system) in seasonal AR (SAR) patients ...
متن کاملClinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis.
BACKGROUND It is unclear what constitutes a clinically meaningful response for allergic rhinitis (AR) outcomes. The objectives of these post hoc analyses were (1) to define a clinically meaningful response using novel efficacy analyses (including a responder analysis), and (2) to compare the efficacy of MP29-02 [a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone pr...
متن کامل